Please ensure Javascript is enabled for purposes of website accessibility

3 Big Pharmas Expecting a Softer 2019

By Cory Renauer – Updated Apr 24, 2019 at 9:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here's why some of the industry's largest players are telling investors not to expect any fireworks this year.

Johnson & Johnson (JNJ 0.05%) kicked off this earnings season with a grim outlook for its pharmaceutical business, and it looks like the trouble has spread to its big pharma peers. More recently, AbbVie (ABBV -0.75%) and Pfizer (PFE 0.73%) told investors not to expect a great deal of sales growth in 2019.

Are these isolated incidents or is the entire pharmaceutical industry in for a year of disappointment? To answer that we need to understand why they're predicting slower sales growth in the first place. Here's what you need to know about the soft-guidance bug that's spreading throughout the biopharmaceutical industry.

A hundred dollar bill hiding under tablets.

Image source: Getty Images.

1. Johnson & Johnson: Payer pushback

Check out the latest Johnson & Johnson earnings call transcript.

The world's largest healthcare conglomerate kicked off earnings season by telling investors its U.S. pharmaceutical segment is trying to walk up an escalator that's going down. Johnson & Johnson made regular price hikes for successful drugs in 2018, but the net price it actually received after insurers applied discounts and rebates fell between 6% and 8% last year. 

Overall, 2018 was a pretty good year for Johnson & Johnson's U.S. pharma division. Despite lower net pricing, higher volume drove U.S. pharmaceutical sales 8.4% higher.

In 2019, though, Johnson & Johnson expects total annual sales to fall 1% to $80.8 billion at the midpoint of its guided range. Net prices sliding across the pharmaceutical segment isn't the only headwind Johnson & Johnson faces right now. A rising dollar is expected to knock about $1.2 billion from reported sales this year.

Sales of the company's top-selling product, Remicade, slid 15.7% to $5.3 billion last year, due to biosimilar competition that probably won't subside soon. Zytiga sales reached $1.8 billion last year in the U.S., but generic versions of the prostate cancer tablet launched late last year. Unlike biosimilars, sales of small-molecule drugs often fall by more than half during their first year of generic competition.

A blister pack full of rolled up dollar bills instead of pills.

Image source: Getty Images.

2. AbbVie: Biosimilar pressure

Check out the latest AbbVie earnings call transcript.

AbbVie hasn't complained much about pushy U.S. insurers demanding higher rebates, although it probably could. Instead, AbbVie's softer-than-expected outlook for 2019 is the result of stingy end payers throughout Europe.

Biosimilar versions of AbbVie's top-selling anti-inflammatory injection, Humira, went on sale throughout the EU in the middle of the fourth quarter. Compared with the previous-year period, international Humira sales fell 17.5%, to $1.3 billion.

At around 15% of total revenue, sagging international Humira sales will create a headwind that AbbVie can probably overcome. In 2018, U.S. Humira sales rose 10.7% to $13.7 billion, and this huge revenue stream will probably continue growing until 2023. 

AbbVie thinks biosimilar competition will reduce total sales by around $2 billion this year, which will probably be offset by a couple of blood cancer drugs that recently received some important label expansions. AbbVie could also launch two potential blockbusters before the end of the year and, if approved, total sales could rise by single digits in 2019.

Person with head on table in front of a downward-sloping chart.

Image source: Getty Images.

3. Pfizer: Lyrica pain

Check out the latest Pfizer earnings call transcript.

Pfizer's top line rose just 2% in 2018, and in 2019 the company expects total revenue to remain flat. Altogether, generic competition for older drugs is expected to reduce total sales by $2.6 billion this year.

One of Pfizer's top sellers, Lyrica, loses U.S. market exclusivity in June, and it's going to sting. Sales of the nerve-pain drug reached $4.9 billion last year, which was about 9% of Pfizer's total revenue for the period. 

Pfizer really isn't exposed to much biosimilar competition -- in fact, it's one of the companies applying pressure. Some of Johnson & Johnson's Remicade losses are a result of competition from Pfizer's Inflectra, a biosimilar version of the popular injection priced at a significant discount.

Don't let go now

Although competition for drugs that lose market exclusivity is a common theme here, these are company-specific events. When it comes to rebate pressure, we really can't say much about AbbVie and Pfizer because they haven't unveiled their gross-to-net-price differences the way Johnson & Johnson has.

Company Forward PE Ratio Dividend Yield Cash Dividend Payout Ratio
Johnson & Johnson 15.2 2.7% 51%
AbbVie 8.9 5.5% 43%
Pfizer 13.4 3.5% 51%

Data source: Yahoo! Finance.

Johnson & Johnson, AbbVie, and Pfizer may be heading into a rough patch caused by patent expirations and other threats, but that doesn't mean you should let go of their shares right now. All three big pharma stocks are trading at below-average multiples of their earnings expectations for the year ahead, and their dividend programs are well funded. 

It isn't easy watching your stocks flounder for a year or longer, but you can count on these three to raise their quarterly payouts going forward. Johnson & Johnson hasn't gone a year without raising its payout since JFK was in office, and it's hardly against the wall now.

Johnson & Johnson used just 51% of free cash flow to make dividend payments over the past year, which means it can keep raising the payout even if total revenue goes nowhere for years on end. AbbVie and Pfizer offer even higher yields right now that could contribute to market-beating returns over the long run.

Cory Renauer owns shares of Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Stock Quote
$49.57 (0.73%) $0.36
Johnson & Johnson Stock Quote
Johnson & Johnson
$177.33 (0.05%) $0.09
AbbVie Stock Quote
$158.43 (-0.75%) $-1.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.